New AveXis data at AAN showed long-term durability of Zolgensma® in patients with spinal muscular atrophy (SMA) Type 1

Tuesday, May 7, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

- Interim long-term follow-up data showed all enrolled Cohort 2 patients maintained motor function and milestones achieved during the Phase 1 START trial

Central

North America

Samir Shah

+41 61 324 7944

Richard Pulik

+1 862 778 3275

Pierre-Michel Bringer

+41 61 324 1065

Cory Twining

+1 862 778 3258

Thomas Hungerbuehler

+41 61 324 8425

Isabella Zinck

+41 61 324 7188



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store